More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has ...

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer Inc. (NYSE:PFE – Get Free Report ... and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs ...

Pfizer is particularly witnessing strong demand for Padcev. Among other acquired products, Nurtec sales are likely to have risen, driven by strong demand in the United States and launches in ...

BNTX), Pfizer has shaped healthcare for decades. Its $43 billion acquisition of Seagen in 2023 bolstered its oncology pipeline, while its RSV vaccine Abrysvo and migraine treatment Nurtec ...

Pharmaceutical companies have stepped up pressure on the Government to push back against proposed new regulations of the sector, which pharma giant Pfizer privately warned could damage the Irish ...

Pfizer spent $11.6bn acquiring Biohaven and its migraine franchise – lead candidate Nurtec earned ~$1.3bn in 2024 – and made a $5.4bn deal for Global Blood Therapeutics and its ~$200m per ...